Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of ExAblate Focused Ultrasound Ablation of Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01620359
Recruitment Status : Completed
First Posted : June 15, 2012
Last Update Posted : August 31, 2016
Information provided by (Responsible Party):

Brief Summary:

The goal of this prospective, non-randomized, single-arm, multi site, international study is to develop data to evaluate the safety and effectiveness of the ExAblate MRgFUS system in the ablation of breast cancer and of MRI.

The goal of MRgFUS ablation of breast cancer is to plan and ablate the entire tumor volume in a treatable and device accessible location.

Condition or disease Intervention/treatment Phase
Breast Cancer Device: ExAblate MRgFUS Phase 2

Detailed Description:
In this international, non-randomized, single-arm study, a total of 200 patients with a positive diagnosis of invasive breast cancer with a scheduled surgical resection will be enrolled into the trial. Eligible participants will be evaluated and treated with ExAblate breast ablation prior to their planned definitive surgical treatment. After the 10 to 21 days post ExAblate therapy, study participants will have another contrast-enhanced MR imaging examination. Their planned tumor excision will then be completed no later than 14 days from the contrast-enhanced, post ExAblate procedure MR imaging examination. Additionally, the end points of the study will be compared against the CORE Pathology Lab results.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of ExAblate Focused Ultrasound Ablation of Breast Cancer Under MR Guidance (MRgFUS) and MRI Evaluation of Ablation
Study Start Date : June 2011
Actual Primary Completion Date : July 2016
Actual Study Completion Date : July 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: ExAblate Device: ExAblate MRgFUS
100% ablation of an up-to-2-cm breast cancer visible on an contrast-enhanced MRI with 5-10 mm margins around the primary tumor

Primary Outcome Measures :
  1. Adverse Events [ Time Frame: 5 weeks post treatment ]
    To evaluate the incidence and severity of the ExAblate MRgFUS device-related complications to establish the safety profile of the ExAblate ablation of breast cancer visible on contrast-enhanced MRI with 5-10 mm margins around the primary tumor

  2. Histopathological analyses [ Time Frame: 5 weeks post treatment ]
    To estimate the effectiveness of ExAblate MRgFUS to ablate 100% of an up-to-2-cm breast cancer visible on an contrast-enhanced MRI with 5-10 mm margins around the primary tumor.

Secondary Outcome Measures :
  1. MR imaging [ Time Frame: 5 weeks post treatment ]
    To estimate the sensitivity of post-ablation MRI in identifying residual disease following ablation.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Women age 18 years with invasive breast cancer
  2. Patient with contrast-enhanced MR imaging confirming a single focal breast lesion less than 2 cm in diameter
  3. Lesion clearly seen on contrast-enhanced MR and in a treatable location
  4. Patient who is willing to undergo and be scheduled for sentinel lymph node biopsy
  5. Patient scheduled and consented to surgical (lumpectomy or mastectomy) resection of the breast cancer
  6. Patient with clinical Stage I disease: T1 M0 N0
  7. Patient who signs an informed consent form for screening, SLNB, ablation, and follow-up visits.

Exclusion Criteria:

  1. Invasive lobular carcinoma;
  2. DCIS without invasive components on core biopsy;
  3. Tamoxifen, Aromatase Inhibitors, and Neoadjuvant chemotherapy within 30 days prior to ExAblate.
  4. Prior XRT or ablative therapy to the target breast;
  5. Patients currently receiving anticoagulation therapy within the previous 14 days;
  6. Lesions difficult to target (<1 cm from skin, nipple or the rib cage), as visualized on pre-therapy MRI;
  7. Microcalcifications as the only sign of breast cancer on imaging studies;
  8. Extensive intraductal components (EIC) on core biopsy.
  9. Patients with breast implants;
  10. Patients with prior surgical clips or other markers at the site of the breast tumor;
  11. Patients with severe cerebrovascular disease (multiple CVA or CVA within 6 months);
  12. hemolytic anemia (hematocrit < 30);
  13. Pregnant or lactating, post-partum women;
  14. Patient overall health status of ASA >2
  15. Patient with active and ongoing infection at any body site;
  16. Poor blood glucose control.
  17. Severe hypertension
  18. Patients with unstable cardiac status
  19. Contraindication to MR or ExAblate ablation therapy
  20. Patient with history of deep vein thrombosis
  21. With history of pulmonary embolism;
  22. Patient with sleep apnea;
  23. Patient with airway problems;
  24. Patient with severe claustrophobia;
  25. Patient with non-MRI compatible implanted metal devices;
  26. Patient with difficulty lying prone and still for up to 3 hours (180 minutes) in the MR unit;
  27. Patient who cannot fit comfortably in the magnet or patients >250 lbs;
  28. Patient with prior reaction to contrast agent;
  29. Patient with history of grand mal seizures;
  30. Patient with severely impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2 and/or who is on dialysis;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01620359

Layout table for location information
Bottrop, Germany, 46236
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Hans Kolberg, MD FUS BOTTROP
Additional Information:
Layout table for additonal information
Responsible Party: InSightec Identifier: NCT01620359    
Other Study ID Numbers: BC006
First Posted: June 15, 2012    Key Record Dates
Last Update Posted: August 31, 2016
Last Verified: August 2016
Keywords provided by InSightec:
Breast cancer
Breast tumor
stage 1 disease
T1 M0 N0
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases